Biohaven Ltd. (NYSE:BHVN) partners with Bexorg Inc. for CNS drug discovery using a novel whole-brain platform. Bexorg’s technology extracts high-resolution insights in disease-relevant states, crucial for ML and AI-centered CNS drug development. BHVN focuses on immunology, neuroscience, and oncology therapies globally. Investors are encouraged to explore undervalued AI stocks for potential growth.

Read more at Yahoo Finance: Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform